FdaApplication
NDA 020152
Identifiers
- fda_app_no: NDA020152
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE |
| application_type | NDA |
| approval_date | 1994-12-22 |
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SERZONE | NEFAZODONE HYDROCHLORIDE | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| SERZONE | NEFAZODONE HYDROCHLORIDE | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| SERZONE | NEFAZODONE HYDROCHLORIDE | 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| SERZONE | NEFAZODONE HYDROCHLORIDE | 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| SERZONE | NEFAZODONE HYDROCHLORIDE | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| SERZONE | NEFAZODONE HYDROCHLORIDE | 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
6 products